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ABSTRACT
Background: The United States Food and Drug Administration (FDA) has warned about the increased suicidality risk associated with the use of selective 
serotonin reuptake inhibitors (SSRI) and venlafaxine in children and adolescents. Objectives: To critically appraise the available evidence supporting the FDA 
Black box warning concerning to the use of antidepressants in child and adolescents. Methods: A critical review of articles in Medline/PubMed and SciELO 
databases regarding the FDA Black box warning for antidepressants, and the impact of FDA warnings on antidepressant prescriptions and suicide rates. Results: 
The warning was based on surveys that did not report either cases of suicide nor a significant difference supporting an increased suicidality rate. The concept was 
defined in an ambiguous way and there is currently more available evidence to support such definition. The use of SSRI and venlafaxine has been associated to 
lower suicidality rates, but the prescription fall due to the warning increased suicide rates. Discussion: Suicidality is an inherent feature of depressive disorders 
so it would be desirable to consider how much of the phenomenon may be attributed to antidepressants per se. It would be appropriate to consider that suicide 
rates might increase also as a consequence of the warning.
Martínez-Aguayo JC et al. / Arch Clin Psychiatry. 2016;43(3):60-6
Keywords: Antidepressants, serotonin uptake inhibitors, suicide, United States Food and Drug Administration.
Introduction
Approximately 2 to 3% of children and 6 to 8% of teenagers suffer 
from major depressive disorder, considered the main determinant 
of suicide, and a leading cause of death among teenagers1. In fact, 
depression is present among 46 to 64% of suicidal adolescents2-4; an 
increase of over twenty times the risk of completed suicide5. Thus, 
suicidal conduct is included in the fifth edition of the Diagnostic 
and Statistical Manual of Mental Disorders as a diagnostic criterion 
to the affective disorders6.
While a positive correlation exists between the risk of suicide and 
the severity of affective disorders, subsequent treatment plays a role as 
a preventive measure. The introduction of new antidepressants (AD), 
particularly selective serotonin reuptake inhibitors (SSRI) have been 
a useful mechanism in the rehabilitation of depression, with some 
countries observing a decrease in suicide rates7. 
Until the 1980s, depression was primarily treated with AD such 
as monoamine oxidase inhibitors and tricyclics. Since overdoses 
of these drugs are potentially lethal, in some cases they were even 
used as a way to carry out suicidal acts, a situation still worrisome 
among prescribers, and which opened a discussion surrounding 
suicidality8-10. Nevertheless, the notion that AD precipitate suicide in 
depressed people was noted by Kielholz and Battegay as early as 1958, 
relating it to “the rollback phenomenon”, which describes the risk 
associated with these medications in mobilizing severely depressed 
patients to attempt suicide as a consequence of psychomotor 
improvement during the first period of therapy, while still affectively 
impaired11.
The SSRI do not escape from inclusion in the discussion of 
suicide, on the grounds that Teicher et al. reported six cases of patients 
with suicidal ideas being treated with fluoxetine, highlighting that 
none had presented such phenomenon previously12. That report 
induced the United States Food and Drug Administration (FDA) 
to create a panel of experts that gave neither recommendations nor 
warnings regarding the drug. This despite blind randomized trials 
which repudiated a link between previously mentioned AD and 
increased suicidality13. Subsequently, in 2004, the FDA created a new 
advisory committee that led to one of the most contentious debates 
linked to suicide: the association between SSRI consumption and the 
inducement of suicide in children and adolescents14. The current FDA 
warning alludes to an increase in suicidality, a vague concept ranging 
from mere ideation to the completion of suicide10-11, despite the lack 
of epidemiologic evidence showing a relationship between suicide 
rates and the prescription of new AD medications15. 
This intent of this review is to provide a critical viewpoint 
concerning the FDA warning, its supporting evidence in terms of 
therapeutic (AD prescription) and epidemiological outcome (suicide 
rates), the studies that support it, and the research that reinforces 
the usage of AD. 
Methods
An exhaustive bibliographic search was done through the available 
articles on the database PubMed, Cochrane Central, SciELO, 
and on specialized consulting texts, using key words as “suicide”, 
“adolescence”, “antidepressants” and “FDA”. The date range of the 
search was from January 1988 through June 2014. 
Results
Black box warning issued by the FDA
In 2003, the United Kingdom’s Department of Health and the FDA 
issued a public warning against the use of paroxetine in people 
younger than 18 years old. In August of the same year, Wyeth 
Laboratories, manufacturer of venlafaxine (dual AD), suggested 
that physicians should cease prescribing the aforementioned drug 
in children and adolescents, due to low efficacy and the risk of 
increasing hostile feelings and suicidal tendencies. Yet in October, 
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the FDA issued research results involving citalopram, fluoxetine, 
fluvoxamine, nefazodone, sertraline and venlafaxine, recommending 
physicians to be cautious in prescribing an AD, with insufficient data 
supporting the thesis of suicide increase16. In December, the British 
Medicines and Healthcare Products Regulatory Agency suggested 
that physicians cease prescribing AD for people younger than 
eighteen (excluding fluoxetine), based on three investigations that 
cited an apparent increase in suicidal tendencies among children and 
adolescents17. However, the only one of these investigations that were 
published examined paroxetine versus placebo in the treatment of 
major depressive disorder, and reported a 3% increase of suicidality 
for the AD (fourteen out of 378 patients) versus 2.5% for the placebo 
(seven out of 285 patients), indicating no statistically significant 
difference18. Additionally, the definition of suicidality or suicidal 
tendencies used was confusing, and included self-harm, suicidal 
planning and ideation, attempt or completed suicide. Neither of 
reports stated any death from suicide18,19.
The FDA alert, called the Black Box warning, was based on 
short-term investigations (between four and sixteen weeks) that 
showed a higher risk of suicidal tendencies (4% on average), 
the double researched for a placebo, without any accomplished 
suicides reported20. Such action provoked a marked decrease in AD 
prescription21. The American Medical Association and the American 
Psychiatric Association subsequently warned of the potentially negative 
consequences that a decline in AD access could have on patients, who 
might otherwise be significantly benefited by their prescription22.
Finally, in October 2004, after assessing a total of 24 studies, the 
FDA extended the Black Box warning to encompass all AD prescribed 
to people younger than eighteen. Many of these investigations 
have not been unveiled to the scientific community, so their 
methodological rigour could be arguable23. In February 2005, the 
warning was modified by the FDA, stating in a more precise way that 
the usage of AD would produce an increase in suicidal tendencies and 
ideations, but not in accomplished suicides24. In Table 119 suicidal risks 
for some AD are described, whereas Table 2 shows the results obtained 
by the FDA when re-analyzing the related events with suicidal acts 
in young people under AD treatment. For general pathologies the 
relative risk of suicidal events ascended up to 1.95, without witnessing 
a statistical superiority with placebo in any case23. 
In a systematic FDA review, 24 studies were included, of nine 
SSRI and other AD families, with a total of 4,582 patients with anxiety 
and affective disorders. Their results showed a relative risk of suicidal 
behavior and ideation, and self-aggressive behaviors associated with 
the usage of SSRI in major depressive disorder above 1.66 (CI 95%, 
1.02 – 2.68), whereas the relative risk in the total of AD examined 
for all evaluated pathologies was 0.002 (CI 95%, 0.01 – 0.03). At 
the same time, the Treatment for Adolescents with Depression 
Study, a multicenter randomized trial testing the efficacy of AD, 
reported a statistically significant higher relative risk for SSRI25. 
Also, a systematic review conducted by Hetrick et al, which looked 
at nineteen trials of a range of newer AD compared with placebo, 
with a total of 3,335 participants showed that those treated with AD 
had lower depression severity scores and higher rates of response/
remission than those on placebo. However, there was evidence of an 
increased risk (58%) of suicide-related outcomes for those on AD. 
Nevertheless, the study’s trials excluded young people at high risk of 
suicide and many co-morbid conditions, so participants were likely 
to be less unwell than those seen in clinical practice. Participants had 
limited information about the risk of bias, high dropout rates and 
issues regarding measurement instruments and the clinical usefulness 
of outcomes, which were often defined differently across trials. The 
authors concluded that: 1) Due to the methodological limitations 
of the included trials in terms of internal and external validity, the 
results must be interpreted with caution; 2) The size and clinical 
meaningfulness of statistically significant results are uncertain; 3) 
Fluoxetine might be the medication of choice if a decision to use 
medication is agreed given the guideline recommendations26. On the 
other hand, an independent meta-analysis, that included 39 studies 
of AD, did not reveal any significant difference in the ideation or risk 
of attempted suicide, where one in 147 patients would demonstrate 
an increased risk27. Dubicka et al. pointed out similar findings about 
pediatric depression, examining the suicidal and self-aggressive 
conduct rates. Total frequency for these events was 4.8% with an 
AD and 3% with a placebo. When using heterogeneity-sensitive 
random effects analysis, the relative risk did not encounter statistical 
significance (RR = 1.58; p = 0.083)28.
In May 2012, the American Academy of Child and Adolescent 
Psychiatry made a public announcement stating that SSRI and other 
AD would be useful in the treatment of depression29, suggesting that 
therapies with AD continue, but include informing and explaining to 
the patient’s family the existing warning. Moreover, it was advised not 
to apply such warnings to all children prescribed AD for depression 
based on: 1) evidence that all AD are efficient in major depression 
(mainly supported for studies in people above eighteen years old); 
2) The study reporting exacerbation of suicidal events does not have 
sufficient statistical power. Most psychiatrists think that if, in some 
cases that statement might be true, it is preferable to monitor them 
rather than to suppress therapy; 3) According to the FDA, only 2% to 
3% of children and adolescents increased their suicidal ideations or 
self-aggressive behaviors after using AD, having no reports of actual 
suicide; 4) The cost of patients’ depression is higher than an increase 
of 2% in suicidality; 5) At the onset of ideation or suicidal behavior 
in the beginning of AD treatment, or after a dose adjustment, close 
surveillance of the patient is recommended during the first month. 
This is to provide a list of alarm symptoms to be alert to, such as the 
appearance of or increase in symptoms such as anxiety, panic attacks, 
psychomotor agitation, akathisia, insomnia, irritability, hostility or 
aggressiveness, impulsivity, hypomania, and mania. Despite the 
aforementioned facts, there is no causal link between these symptoms 
and ideation or suicidal behavior; 6) If the symptoms were severe, 
had an abrupt start or were not initially present, a change in the 
therapeutic plan should be considered30,31.
Finally, in 2014 the results of a retrospective investigation were 
published that considered 36,842 children from ages six to eighteen 
who used fluoxetine, sertraline, paroxetine, citalopram, escitalopram, 
and venlafaxine, all of which were included in the FDA warning 
(fluoxetine is the only allowed AD to be prescribed in children and 
Table 1. Suicidality rate according to antidepressant versus placebo
Drug N Suicidalitya 
Antidepressant 
(%)
Suicidalitya 
Placebo (%)
P value
Fluoxetine 458 3.6 3.8 0.9
Sertraline 373 2.7 1.1 0.45
Citalopram 418 8.9 7.3 0.4
Paroxetine 663 3.7 2.5 0.5
Venlafaxine 334 2 0 0.25
a Ideation, suicide attempt or self-harm. Modified from Brent y Birhamer19.
Table 2. Relative risk for suicidal behaviors on clinical trials according to 
antidepressant
Antidepressant Major depression studies All pathologies studies
Citalopram 1.37 1.37
Fluvoxamine No research 5.52
Paroxetine 2.15 2.65
Fluoxetine 1.53 1.52
Sertraline 2.16 1.48
Venlafaxine XR 8.84 4.97
Mirtazapine 1.58 1.58
Nefazodone No events No events
Bupropion No research No events
Total 1.66 1.95
Modified Cheung et al.23.
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adolescents by FDA). The research stated that the rates of attempted 
suicide did not differ significantly among people who received 
fluoxetine and the other AD not recommended by the FDA32. 
Evidence that supports the usage of antidepressants
The individual risk of suicide is multifactorial, but depression stands 
out as an important factor. Considering that the methodological 
quality of the research on AD therapy has improved since the warning 
issued by the FDA, the aspects that support the usage of AD will be 
described33.
Usage of antidepressants and decrease in suicidal rates
Despite the FDA warnings, there is much AD treatment that results 
in reducing suicide risks. Thus, in the “Antidepressant Age” (1960-
1992) suicide rates associated with affective disorders were reduced 
from 6.3 per thousand at the beginning of the Twentieth Century 
to 3.3 per thousand34,35. In a study, Kuba et al. found that suicidal 
ideation, self-mutilation and suicide attempts decreased from 47.1% 
to 22.9% after three months of AD therapy in patients with a mean 
age of 15.4 years36.
The Centers for Disease Control and Prevention indicate that 
the suicide rate of teenagers increased throughout the 1970’s and 
1980’s14, followed by its decrease of 20% to 30%37 associated with 
the introduction of SSRI in 198838-41. In fact, between 1985 and 
1999, the suicide rate in the US decreased from 12.4 to 10.7 per 
100,000, while the prescription of AD (predominantly SSRI) was 
quadrupled42. In North American teenagers, for every 1% increase 
in AD prescription, there was a decrease of 0.23 suicides per 100,000 
annually (p < 0.001)43,44. Additionally, the 13% increase in SSRI 
sales in 27 countries during 1999 reduced suicide rates by 2.5% in 
those countries. Particularly in Sweden, suicide fell by 25%, which 
was likely associated with the 400% increase in AD sales there45. 
Likewise, Bramness et al., through observations made in Norway 
between 1980 and 2004, found a significant relationship between the 
rise of non-tricyclic AD sales and the decreased suicide rates46. On 
the other hand, SSRI were introduced in Japan in 1999, increasing 
its AD prescription by 54%. According to the Japanese Ministry of 
Health, suicide rates after that year decreased by 6%47.
Elapsed time in antidepressant treatment
Simon et al. established a temporal correlation between the usage 
of AD and suicide rates, reporting that the instances of suicide were 
significantly lower than the month prior to the beginning of AD 
treatment. In a total of 65,103 users of AD, the suicide risk during 
the acute phase of the treatment was one per 3,000, while the suicide 
attempt was one per 1,000, without a significant association between 
an increase in these risks and SSRI therapy. Meanwhile, the suicide 
risk of children and teenagers during the six months following 
antidepressant indication was 314 per 100,000, this being higher 
than the month previous to the prescription, showing a decrease 
immediately after onset of medication and a decline during its usage. 
While the estimated risk remained relatively stable over the next six 
months, their confidence intervals were wide, validating the lack to 
the number of observed events. Researchers assert that a significant 
increase of suicide risks or serious suicidal attempts existed after 
initiating SSRI therapy48. These findings were confirmed by Simon 
& Savarino, thus proving the reduction in the suicide rate after AD 
treatment49. Similarly, Jick et al. found a strong relationship between 
suicidal behavior and the time elapsed since the beginning of the 
AD therapy. Compared to a group that had accomplished ninety or 
more days of treatment, those who had between one and nine days 
were four times more likely to commit a non-fatal suicidal act, while 
those that completed between ten and twenty-nine days were three 
3 times more likely, and those who completed reached between 30 
and 89 days of treatment only 1.5 times more likely. Moreover, those 
who had between one and nine days of treatment were 38 times more 
likely to commit suicide, those treated between ten and twenty-nine 
days, were 5.1 times more likely, and finally, those that completed 
between 30 and 89 days, twice as likely50.
Usage of particular drugs in high risk cases
Mines et al. compared a series of clinical parameters and morbidity 
records in patients assigned to fluoxetine, citalopram and venlafaxine. 
The venlafaxine patients group was considered to be the most severe 
due to their psychopathological history with increased suicide 
risk. Confirming that statement, those treated with fluoxetine and 
citalopram showed 2.75 times and 2.43 times less suicidal behavior 
respectively, compared to those who received venlafaxine51.
Venlafaxine has been one of the most criticized AD by the 
FDA. Nevertheless, it has considerable prestige among clinicians 
for the treatment of severe depression, due in part to its being often 
prescribed to high-risk groups. Patients assigned to venlafaxine had 
6.19 times more risk of being hospitalized for depression compared 
to patients assigned to fluoxetine, and 4.34 times more than those 
who received citalopram. Regarding drug history, 27.7% of the 
group of venlafaxine patients received two or more AD during the 
last year, while among fluoxetine and citalopram users, 5.5% and 
11% respectively, reported such use. Table 3 illustrates the relative 
risks for general characteristics and behaviors related to suicide for 
venlafaxine, fluoxetine and citalopram51.
Low plasma levels of antidepressants and discontinuation
Several toxicological studies have revealed that a low proportion of 
suicide victims had considerable plasmatic levels of AD, indicating 
that a large number of suicides occurred in people that were depressed 
and receiving no treatment, failed to adhere to indications, or who had 
discontinued the medication52-55. Relatedly, Isacsson et al. conducted 
post-mortem studies of suicides, and did not find plasmatic levels of 
SSRI in children below fifteen years old, while in the group between 
fifteen and nineteen years of age, the presence of SSRI was minor 
compared to other types of AD. This suggests that the hypothesis of 
suicide being induced by SSRI was not supported by autopsy data56, 
while also concluding that the increase in AD usage in Sweden had 
been parallel to a significant decrease in suicide rates there. 
Meanwhile, Leon et al. studied 66 suicides which occurred 
in New York City between 1993 and 1998, the first six years that 
paroxetine was available in the United States. Subjects were under 
eighteen years of age, and chromatographic methods did not find, 
plasma levels of paroxetine57. In other research conducted in New 
York City which looked at 44 suicides among subjects less than 
eighteen years old between 1999 and 2002, in only one case (2,8%) 
was sertraline and bupropion detected during the autopsy, while in 
all others no presence of any other AD was found58. From a sample 
of 1,635 suicide victims, Marzuk et al. showed that 16.4% had a 
psychotropic prescription, thus reinforcing the above evidence. 
From the toxicological analysis only 17.9% of deaths by poisoning 
were found, finding AD in less than half of these victims59. So it 
is supported that the presence of AD in suicidal teenagers is low, 
contradicting any direct relationship between SSRI usage and child 
and adolescent suicide14. Regarding the discontinuance of AD, 
Yerevanian et al. found that the risk of committing suicide increased 
five times after suspending AD therapy, claiming that its use would 
serve as an anti-suicidal protective factor60.
Discussion
“Suicidal tendencies” are central to the FDA’s stance against AD 
prescription, which raises the question: Is suicide an AD side effect 
or attributable to one of the affective disorders? In lieu of attributing 
suicidogenic characteristics to AD, we must bear in mind that 
the regulatory associations do not consider the essential factors 
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Table 3. Risk for behaviors and general characteristics related to suicide according to antidepressant 
Characteristics Venlafaxine
N = 27,096
Fluoxetine
N = 134,996
Citalopram
N = 52,035
Relative risk
N (%) N (%) N (%) Venlafaxine versus 
fluoxetine
Venlafaxine versus 
citalopram
Previous diagnosis
Major depressive disorder 20,574 (75.9) 57,918 (42.9) 27,883 (53.6) 4.10 2.8
Bipolar disorder 423 (1.6) 452 (0.3) 328 (0.6) 4.83 2.51
Schizophrenia 705 (2.6) 1,343 (1) 714 (1.4) 2.70 1.91
Anxiety disorder 10,210 (37.7) 28,788 (21.3) 15,560 (29.9) 2.13 1.45
1-year previous event
Suicidal behaviors 260 (1) 474 (0.4) 207 (0.4) 2.75 2.43
Suicidal behaviors that required hospitalization 99 (0.4) 177 (0.1) 67 (0.1) 2.79 2.84
Hospitalization due to depression 670 (2.5) 551 (0.4) 302 (0.6) 6.19 4.34
Another AD prescribed previously 19,651 (72.5) 37,318 (27.6) 20,563 (39.5) 6.91 4.04
Number of prescribed AD in the last year
0 7,445 (27.5) 97,678 (72.4) 31,472 (60.5) 0.14 0.25
1 12,132 (44.8) 29,836 (22.1) 14,831 (28.5) 2.86 2.03
2 or more 7,519 (27.7) 7,482 (5.5) 5,732 (11) 6.55 3.1
Current drug usage
Mood stabilizers 1,010 (3.7) 1,536 (1.1) 977 (1.9) 3.36 2.02
Anxiolytic 2,740 (10.1) 6,893 (5.1) 4,253 (8.2) 2.09 1.26
Antipsychotic 2,653 (9.8) 3,393 (2.5) 2,230 (4.3) 4.21 2.42
Modified from Mines et al.51.
that research has demonstrated, such as the severity of depressive 
symptoms, existence of initial suicide ideation, despair, impulsivity, 
previous suicide attempts, psychiatric disorder and suicide family 
records, comorbidities with other psychiatric disorders (e.g. alcohol or 
drug abuse), medical pathologies linked to pain, treatment adherence, 
pharmacokinetic parameters (e.g. increased metabolism with lower 
plasmatic concentrations than the therapeutic ones), and time elapsed 
since the onset of treatment61. Neither the psychosocial factors nor 
easy access to any suicidal methods are considered. It is questionable 
to not only attribute suicide to AD per se but to the presence and 
increase of suicidal behaviors, especially sinced these behaviors are 
inherent to mood disorders, estimating that between 60% to 70% of 
depressive people experience suicidal ideation and between10% to 
15% actually commit suicide62. At first glance, the fact that significant 
differences are observed in comparison with placebo may allow one 
to conclude that AD induce suicidality; nevertheless, those findings 
can be methodologically questioned, due to the fact that researchers 
would rarely administer any placebo or AD to groups of patients with 
similar depressive severity due to ethical constraints, rendering them 
hardly comparable. An inherent problem with the FDA’s systematic 
review is the retroactive gathering of relevant information, and the 
lack of a clear definition pertaining to suicide-related events. In this 
sense, only the Treatment for Adolescents with Depression Study63 
comprehensively evaluated the phenomenon from initial quantities of 
suicidal ideation and associated behaviors. Suicide varies individually, 
thus only randomized trials with large sample sizes would have 
enough statistical significance to demonstrate any difference in the 
suicide rates linked to AD versus placebo. Nevertheless, with suicide 
being a low-frequency event, it is difficult to perform a clinical trial 
large enough to obtain a causal hypothesis. This is a problem that 
could be solved through meta-analyses of existing randomized 
clinical trials. However, the period of time clinical trials are usually 
conducted may me insufficient to establish long-term treatment 
benefits. Additionally, suicidal behaviors usually constitute exclusion 
criteria due to their ethical limitations and practical difficulties46.
Multiple factors exist which can be linked to the suicidality 
phenomenon. Firstly, not every AD is effective on any specific 
patient, nor is the prescribed dosage always sufficient to control the 
intensity of the symptoms. Another factor is the pharmacological 
switch from depression to mania (particularly from dysphoric to 
irritable mania) in bipolar patients treated with AD in absence of 
mood stabilizers64, leading to self-aggressive behaviors. In terms of 
treatment temporality, there appears to be an inverted relationship 
between suicidal behaviors and AD exposure time, raising the 
question as to what methodology was used in the studies selected 
by the FDA looking at suicide risk during the first days of therapy 
compared to the risk in people who do not receive AD. Also, unlike 
adults with whom psychiatric assistance is often sporadic, in child and 
adolescent psychiatry the patient is commonly brought to treatment 
by their parents. As such, professional assistance may be sought once 
the responsible adult perceives that there may be a serious clinical 
disorder or it if a suicide attempt has already occurred65,66.
The FDA clinical trials do not reflect sustained treatment, since in 
daily clinical practice the physician may prematurely interrupt the AD 
therapy due to unwanted adverse effects, to adjust the dosage or make 
changes to drug combinations67. It is precisely this type of practice-
based AD treatment that has been successfully applied over the past 
thirty years in high-risk suicide depressive patients, mainly on an 
in-patient basis, whose follow up and control may have otherwise 
been adversely affected due to diverse constraints11. Considering 
that depression is the disorder most-linked to suicide68-70, it is 
reasonable to propose that a close surveillance of the patient could 
be a protector factor against the phenomenon, specially considering 
other variables, such as lack of response for SSRI (20% to 30%)71, 
patient non-compliance (15% to 20%)72 and patients misreport about 
compliance (even higher in adolescents, particularly if there is no 
direct supervision). It is for this reason that fluoxetine, with a longer 
half life than the other SSRI, would not leave a “therapeutic gap” if 
the drug intake is irregular, which helps explain why fluoxetine has 
been the least challenged AD by the FDA. 
Klein argue that the central concern of the FDA is that AD are 
potentially lethal, while it is unsupported by research on any case 
of suicide, instead using the concept of “suicidality” as a substitute 
for “suicide” and thus overestating the risk. Furthermore, the FDA’s 
findings appear to be based on inferences, since the evidence was 
obtained in a manner that is not methodologically reliable, nor 
fulfilling the requirements of the definitions of “suicidal tendencies” 
utilized by the standardized scales22. 
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What factors linked to antidepressants could increase 
suicidality?
Although Khan et al.73 and Gunnell et al.74 concluded that there was 
not an impact on suicide secondary to the use of AD, there was an 
increase of self-aggressive behaviors. Some proposed mechanisms to 
explain the relationship among AD, ideas, and suicidal behaviors75,76, 
are psychomotor stimulation, depression paradoxical deterioration, 
akathisia, panic attack or anxiety onset, pharmacological switch 
to mania, induction to obsessive concern with suicide, and 
aggressive “borderline reactions” or paroxysmal disorders to 
electroencephalogram that might alter impulse control61,73-76. For 
example, AD with short half-lives may induce, initially, serotonin 
level fluctuations, which may lead to akathisia, therefore increasing 
suicidal risk associated with desperation and unrest77.
 In relation to genetic influence, Menke et al. did a genome-wide 
association study to identify genetic markers linked to emergent 
suicidal ideation resulting from the AD treatment, finding a very 
low proportion of genetic factors related to this phenomenon. 
The results suggest that combinations of some genetic markers 
could be used to identify patients with this risk78. Additionally, an 
investigation into clinical and genetic predictors of the increase of 
suicidal ideation by patients undergoing therapy with AD assessed the 
effects of paroxetine, venlafaxine, and clomipramine. The increase of 
suicidality was linked to the severity of the affective disorder and the 
AD treatment when some defined genetic sequences were present, 
with the exception of paroxetine, which did not show a significant 
relationship with the aforementioned risk. Some genome sequences 
were described as stronger guidelines than others in suicidal ideation 
increase across the therapy, whereas others exhibited a differential 
association according to the AD type. The FKBP5 gene that codifies 
proteins linked to glucocorticoid receptor would be associated 
with the misregulation of the hypothalamic-pituitary-adrenal axis 
during AD treatment, and the physiopathological mechanism 
was proposed as responsible for the increase in suicidal ideation. 
Nevertheless, the authors support the AD prescription in patients 
displaying suicidal ideation, taking into account the potential benefits 
of therapy79. Pan et al. described a crucial element of suicidality, 
independent of AD prescription, when reporting a new variant of 
guanosine tryphosphate cyclohidrolase deficiency in young men 
with severe major affective disorder with multiple suicide attempts. 
This deficiency was linked to some biochemical mediators in the 
biosynthetic pathways of serotonin and dopamine in cerebral spinal 
fluid, demonstrating impairment in this metabolic pathway. Through 
the replacement of these mediators, suicidal ideation was lessened 
and there was significant improvement in the affective disorder80. 
Although these investigation trends are interesting, it would be 
overly-reductionist to only consider the biological-molecular aspects 
involved in the comprehension of suicide, regarding the inherent 
biopsychosocial nature of this topic. 
Epidemiological effects following FDA warning
Approximately one month after the FDA warning was published, the 
prescription of AD in the United States had decreased by 10%, and 
by June 2005 it had decreased an additional 10%81. Simultaneously, 
Hamilton et al. noted that after ten years of decrease in the annual 
suicide rates in North American children and teenagers, an increase 
of 18% was observed in people between one and nineteen years of age 
during 2003 and 2004, suggesting that this change may be the result of 
the FDA recommendation82. In a comparative analysis, Gibbons et al. 
found that the usage of SSRI in children and adolescents decreased by 
20% in the Netherlands and the United States, proving a correlation 
with the increase of the 49% and 14% in suicide rates, respectively83. 
Nevertheless, Kurdyak et al. stated that the FDA warning was not 
associated with a significant change in AD prescription in Ontario 
(Canada) in patients under twenty years old. Meanwhile, the British 
warning about the prescription of paroxetine in this population 
contributed to a significant decline in its prescription by 54% 
(p = 0.03) immediately after the first warning by the United Kingdom 
Committee on Safety of Medicines. The authors argue that the drastic 
change in paroxetine usage in contrast with AD prescription was due 
to the British warning being more specific, since it only covered one 
AD. On the other hand, physicians in Ontario could have prescribed 
a substitute for paroxetine, while the FDA warning fell on an AD 
series, thereby leaving professionals without adequate replacement 
treatment options84.
These studies demonstrate a radically diametric effect from the 
warning issued by the FDA. It is clear that a posterior amplification 
of the black box warning had an additional impact on practice. In 
parallel, the FDA recommendation which suggests closer therapeutic 
contact does not consider the current problems of the mental health 
system, including low coverage by insurance plans for mental 
disorders, strict limits on visits to hospitalized and ambulatory 
patients, restricted access to mental health providers, inter alia. 
Additionally, the current deficit in professionals (child and youth 
psychiatrists in particular) is not expected to be reversed in the 
short term, which may be seen as a reason why this tight control 
becomes difficult85.
Conclusions
Aside from being contradictory to present evidence, assigning a 
suicidogenic role to AD implies debugging every biological, social 
and psychological factor that impacts the act of suicide, which itself 
is a multifactorial phenomenon, and thus not attributable to a single 
cause. Indeed, many studies that underpin the FDA’s stance on AD 
and suicide risk are still unknown to the scientific world, while others 
lack a rigorous methodology, or indicate results that do not reach 
statistical significance. Although the therapeutic effects of SSRI and 
venlafaxine in young patients may be limited, reasonable evidence 
does exist which supports its use in the treatment of depression. Based 
on this, the FDA warning itself might paradoxically be contributing 
to an increase in suicide rates.
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